Target Exclusivity. To the extent permitted by applicable law, during the Program Term of any Program, Pieris shall not apply its Anticalin Technology to perform any research or development activities for its own benefit or with or for the benefit of any Third Party on the Target to which the relevant Program relates.
Appears in 2 contracts
Sources: Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.), Collaboration and License Agreement (Marika Inc.)